In this issue:
Age no bar: An analysis of elderly patients undergoing ASCT for MM
Delaying transplant does not confer inferior outcomes in patients who respond to modern induction therapies
Utilization patterns and hospital effects following ASCT in Germany
TOURMALINE-MM4 finds ixazomib postinduction maintenance prolongs PFS in transplant-ineligible MM
Real-world efficacy of ixazomib-based frontline therapy in newly diagnosed MM
Lyophilised belantamab mafodotin elicits a deep and durable response in heavily pre-treated RRMM
Pre-treatment MTB and TLG are superior to conventional PET/CT variables for outcome prediction
Risk of thromboembolism in patients with MM treated with daratumumab
The paradoxical prognostic role of 1q21 gain/amplification
Serum brain-derived neurotrophic factor concentration predicts polyneuropathy and OS
Please login below to download this issue (PDF)